Paper Details

  1. Home
  2. Paper Details

[Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia].

Author: Arteaga SánchezA, Cortés LambeaL, Díaz ValleD, García SáenzS, Lorenzo GiménezS, Segura BedmarM, Toledano FernándezN

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the effectiveness of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in treating recurrent conjunctival intraepithelial neoplasia (CIN) in patients who are resistant or intolerant to topical mitomycin C (MMC).
Paper Details　
Original Abstract of the Article :
To study the efficacy of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in the treatment of recurrent conjunctival intraepithelial neoplasia (CIN) in those patients who present resistance or intolerance to topical mitomycin C (MMC) treatment or when it is not indic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12789630

データ提供：米国国立医学図書館（NLM）

Interferon alfa-2b: A Promising Treatment for Recurrent Conjunctival Intraepithelial Neoplasia

The [recurrent conjunctival intraepithelial neoplasia (CIN)] is a challenging condition, often resistant to conventional therapies. This study explores the efficacy of [topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b)] in treating recurrent CIN in patients who have failed or are intolerant to [mitomycin C (MMC) treatment]. The study aims to provide a viable alternative for patients seeking effective treatment options. The research suggests that IFN alfa 2b may be a promising treatment modality for recurrent CIN.

Interferon alfa-2b: A Novel Approach for Recurrent CIN

The study's results suggest that IFN alfa 2b, either topically or in combination with subconjunctival administration, may be an effective treatment for recurrent CIN in patients who have failed or are intolerant to MMC treatment. This research provides valuable insights into alternative treatment strategies for this challenging condition.

Navigating the Treatment of Recurrent CIN: A New Path Forward

This study highlights the importance of exploring alternative treatment options for recurrent CIN, especially for patients who are not responsive to conventional therapies. The use of IFN alfa 2b, as suggested in this research, could offer a new path forward for effective management of this condition. Further research is needed to fully evaluate its efficacy and safety in a broader patient population.

Dr.Camel's Conclusion

The treatment of recurrent CIN can be a challenging journey, often requiring a search for alternative solutions. This study unveils the potential of IFN alfa 2b as a promising treatment option, offering hope for patients who have not responded to conventional therapies. The research encourages further exploration of this treatment modality to advance the management of recurrent CIN and improve patient outcomes.

Date :
  1. Date Completed 2003-09-24
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

12789630

DOI: Digital Object Identifier

12789630

Related Literature

Article Analysis
・Side Effects of interferon alfa-2b injection
SNS
PICO Info
in preparation
Languages

Spanish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.